SCHEMBL12409334

SCHEMBL12409334

Cc1cn2c(-c3ccc(O)c(F)c3)cnc2c(NCc2ccc(S(N)(=O)=O)cc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KB Q9UBF8 4/20 0.45
TTK P33981 3/20 0.40
NTRK1 P04629 1/20 0.40
NTRK3 Q16288 1/20 0.40
NTRK2 Q16620 1/20 0.40
PTGS2 P35354 3/20 0.39
ALOX5 P09917 1/20 0.39
LTB4R Q15722 1/20 0.39
CA1 P00915 3/20 0.39
CA2 P00918 3/20 0.39
CA9 Q16790 3/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
CDK1 P06493 1/20 0.39
CDK2 P24941 1/20 0.39
GAA P10253 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
STK17B O94768 1/20 0.39
CSF1R P07333 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12409492 0.91 TTK (0.41) PI4KBTTKNTRK1NTRK3NTRK2
SCHEMBL2180513 0.88 CA1 (0.46) PI4KBTTKALOX5LTB4RCA1
SCHEMBL12409331 0.88 FYN (0.47) TTKPTGS2CA1CA2CA9
SCHEMBL12409491 0.85 CA1 (0.40) PI4KBNTRK1NTRK3NTRK2PTGS2
SCHEMBL12409257 0.85 PI4KB (0.53) PI4KBTTKNTRK1NTRK3NTRK2
SCHEMBL12409483 0.82 PI4KB (0.44) PI4KBNTRK1NTRK3NTRK2PTGS2
SCHEMBL12409493 0.80 PTGS2 (0.48) TTKPTGS2PTGS1
SCHEMBL12409495 0.80 PI4KB (0.44) PI4KBTTKNTRK1NTRK3NTRK2
SCHEMBL14668748 0.79 KDM4E (0.47) PI4KBALOX5LTB4RCA1CA2
SCHEMBL2177269 0.78 STK17B (0.47) PI4KBALOX5LTB4RCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS CYP3A5, HAVCR2, CYP3A43 PI4KB 2534/4885TTK 3239/4885NTRK1 3339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.